Ann M Inouye

Biographic Data

ID1845451
NAMEAnn M Inouye
GIVEN NAMESAnn M
FAMILY NAMEInouye
SIGNATUREINOUYE A M
AFFILIATIONSBrown University
ORCID0000-0001-9962-4996
VERIFIEDYes
TOTAL WORKS2
TOTAL CITATIONS0
WORKS AS AUTHOR2
WORKS AS EDITOR0
FIRST PUBLICATION YEAR2023
LATEST PUBLICATION YEAR2024
H-INDEX0

  • MDMA-assisted dialectical behavioral therapy for borderline personality disorder

    Open AccessAnn M Inouye, Aaron Wolfgang et al.ARTICLEJournal of Psychedelic Studies2024

    In 2021, the final series of phase 3 clinical trials looking at MDMA-AT for treatment-resistant post-traumatic stress disorder (PTSD) found that 71.2% of 3,4-methylenedioxymethamphetamine (MDMA) full-dose participants no longer met criteria for PTSD. MDMA-assisted therapy is not US Food and Drug Administration (FDA) approved in treating borderline personality disorder (BPD), and while PTSD is quite different from BPD, it is possible that some of …

  • MDMA-assisted therapy for borderline personality disorder

    Open AccessAnn M Inouye, Aaron Wolfgang et al.ARTICLEJournal of Psychedelic Studies2023

    Associated with high-risk behavior, borderline personality disorder (BPD) remains one of the field's most misunderstood, misdiagnosed, and stigmatized conditions. Individuals with BPD are frequently labeled as treatment-resistant patients. Furthermore, 25-58% of BPD individuals have a comorbid diagnosis of post-traumatic stress disorder (PTSD), and BPD may be conceptualized as a trauma-spectrum disorder. In Phase 3 clinical trials for 3,4-methyle…